<p>/PRNewswire/ -- <strong>美国大麻医学委员会 (ACCM)</strong> 今天强烈支持美国司法部和药品管制局将某些大麻相关产品从《受控物质法》第一类转移到第三类的最终命令。这一具有里程碑意义的决定代表了现代化联邦大麻政策和扩大负责任患者获取的一个重要且久违的步骤。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>倡导医疗大麻及其患者的提升州</p>
<p>根据该命令，FDA 批准的源自大麻的药物和州许可的医疗大麻项目现在将被认定为第三类——承认其被接受的医疗用途，同时保持适当的监管监督。这一转变使联邦政策与当今医疗保健环境的现实更加紧密相连，绝大多数州已建立了强大的医疗大麻框架，为数百万患者提供服务。</p>
<p>“这是患者、提供者和更广泛医疗系统的关键时刻，” ACCM 外联委员会联合主席迈克·巴特勒表示。“将其重新分类为第三类验证了支持医疗大麻的日益增长的科学和临床证据，同时使其能够负责任地融入主流护理的下一个阶段。”</p>
<p><strong>促进患者获取和医疗整合</strong></p>
<p>重新分类的行动预计将：</p>
<ul>
<li>扩大医生指导的医疗大麻治疗选择的获取</li>
<li>加速临床研究和药物开发</li>
<li>降低医疗提供者参与以患者为中心的大麻护理的障碍</li>
<li>支持医疗大麻在保险和健康计划中的更广泛纳入</li>
</ul>
<p><strong>促进可持续行业增长</strong></p>
<p>该命令还为医疗大麻生态系统提供了关键的结构性改善，包括：</p>
<ul>
<li>为州许可运营商减轻《第 280E 条》税收限制</li>
<li>与现有州许可系统相一致的新快速联邦注册途径</li>
<li>通过协调的联邦和州监管减少监管摩擦</li>
</ul>
<p>这些变化将使合规运营商能够重新投资于患者护理、产品质量和创新，同时增强行业的透明度和问责制。</p>
<p><strong>未来的基础</strong></p>
<p>ACCM 强调，这一行动不是终点，而是持续进步的基础。该组织将继续与政策制定者、医疗领导者和行业利益相关者合作，推动支持安全、有效和公平获取医疗大麻的标准、教育和基础设施。</p>
<p>“将大麻重新分类为第三类是一个久违的步骤，为真正的科学打开了大门。多年来，研究人员一直被阻止研究其全部治疗潜力。” ACCM 研究委员会主席安娜贝尔·马纳洛 - 摩根博士表示。“现在，我们可以生成数据，负责任地进行教育，并确保获取是基于证据而非污名。这是患者、科学和全球健康的胜利。”</p>
<p>ACCM 仍致力于推进其国家倡议，包括提升州计划和下一个前沿平台，以支持医疗大麻在医疗和健康系统中的标准化、合规和以患者为中心的整合。</p>
<p><strong>关于美国大麻医学委员会 (ACCM)</strong></p>
<p>美国大麻医学委员会是美国医疗大麻行业的主要声音，代表零售商、生产商、医疗专业人士、研究人员、保险公司、患者倡导者和健康提供者的联盟。ACCM 的下一个前沿计划和平台提供了数字连接药房、保险公司、健康团体和医生以便患者获取的基础设施系统。</p>
<p>ACCM 成立于 2016 年，作为国会山的工作组，已发展成为一个国家组织，致力于通过政策推进、医生参与、患者倡导和促进患者安全、获取和创新的标准发展，扩大安全、有效和公平获取医疗大麻的机会。</p>
<p><strong>了解更多：</strong></p>
<p><strong>提升州计划：</strong> www.elevatedmembership.org <strong>下一个前沿计划：</strong> www.nextfrontier.us</p>
<p><strong>美国大麻医学委员会</strong></p>
<p><strong>媒体联系人：</strong></p>
<p>莱克西·亨德森</p>
<p>202-349-9650 ext. 800</p>
<p>[email protected]</p>
<p>来源 美国大麻医学委员会</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIzJk5ld3NJdGVtSWQ9UEg0MjM4MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjMxMzExUFJfTkVXU19VU1BSX19fX19QSDQyMzgw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIzJk5ld3NJdGVtSWQ9UEg0MjM4MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjMxMzExUFJfTkVXU19VU1BSX19fX19QSDQyMzgw"/></p>

纯美国大麻 ETF

纯大麻 ETF - AdvisorShares

WEED

<p>美国大麻医学委员会（ACCM）支持美国司法部将某些大麻产品从第一类药物重新分类为第三类药物的决定。这一变化承认了 FDA 批准的以大麻为基础的药物的医疗用途以及各州许可的医疗大麻项目。重新分类预计将增强患者的获取渠道，加速研究，并减少医疗服务提供者的障碍。ACCM 强调，这是将医疗大麻纳入主流医疗保健的基础性步骤，促进行业的负责任获取和创新</p>

<p>, /PRNewswire/ -- The <strong>American Council of Cannabis Medicine (ACCM)</strong> today strongly supports the U.S. Department of Justice and Drug Enforcement Administration's final order to move certain marijuana-related products from Schedule I to Schedule III under the Controlled Substances Act. This landmark decision represents a meaningful and long-overdue step toward modernizing federal cannabis policy and expanding responsible patient access.</p>
<div class="lb-trans"><p>/PRNewswire/ -- <strong>美国大麻医学委员会 (ACCM)</strong> 今天强烈支持美国司法部和药品管制局将某些大麻相关产品从《受控物质法》第一类转移到第三类的最终命令。这一具有里程碑意义的决定代表了现代化联邦大麻政策和扩大负责任患者获取的一个重要且久违的步骤。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Elevated States Advocating Medical Cannabis and it's Patients</p>
<div class="lb-trans"><p>倡导医疗大麻及其患者的提升州</p>
</div><p>Under the order, FDA-approved cannabis-derived medications and state-licensed medical marijuana programs will now be recognized under Schedule III—acknowledging their accepted medical use while maintaining appropriate regulatory oversight. This shift aligns federal policy more closely with the realities of today's healthcare landscape, where a majority of states have established robust medical cannabis frameworks serving millions of patients.</p>
<div class="lb-trans"><p>根据该命令，FDA 批准的源自大麻的药物和州许可的医疗大麻项目现在将被认定为第三类——承认其被接受的医疗用途，同时保持适当的监管监督。这一转变使联邦政策与当今医疗保健环境的现实更加紧密相连，绝大多数州已建立了强大的医疗大麻框架，为数百万患者提供服务。</p>
</div><p>&#34;This is a pivotal moment for patients, providers, and the broader healthcare system,&#34; said Mike Butler, ACCM Outreach Committee, Co-Chair. &#34;Rescheduling to Schedule III validates the growing body of scientific and clinical evidence supporting medical cannabis while enabling the next phase of responsible integration into mainstream care.&#34;</p>
<div class="lb-trans"><p>“这是患者、提供者和更广泛医疗系统的关键时刻，” ACCM 外联委员会联合主席迈克·巴特勒表示。“将其重新分类为第三类验证了支持医疗大麻的日益增长的科学和临床证据，同时使其能够负责任地融入主流护理的下一个阶段。”</p>
</div><p><strong>Advancing Patient Access and Medical Integration</strong></p>
<div class="lb-trans"><p><strong>促进患者获取和医疗整合</strong></p>
</div><p>The rescheduling action is expected to:</p>
<div class="lb-trans"><p>重新分类的行动预计将：</p>
</div><ul>
<li>Expand access to physician-guided medical cannabis treatment options</li>
<li>Accelerate clinical research and pharmaceutical development</li>
<li>Reduce barriers for healthcare providers to engage in patient-centered cannabis care</li>
<li>Support broader inclusion of medical cannabis within insurance and wellness programs</li>
</ul>
<div class="lb-trans"><ul>
<li>扩大医生指导的医疗大麻治疗选择的获取</li>
<li>加速临床研究和药物开发</li>
<li>降低医疗提供者参与以患者为中心的大麻护理的障碍</li>
<li>支持医疗大麻在保险和健康计划中的更广泛纳入</li>
</ul>
</div><p><strong>Enabling Sustainable Industry Growth</strong></p>
<div class="lb-trans"><p><strong>促进可持续行业增长</strong></p>
</div><p>The order also delivers critical structural improvements for the medical cannabis ecosystem, including:</p>
<div class="lb-trans"><p>该命令还为医疗大麻生态系统提供了关键的结构性改善，包括：</p>
</div><ul>
<li>Relief from Section 280E tax restrictions for state-licensed operators</li>
<li>A new expedited federal registration pathway aligned with existing state licensing systems</li>
<li>Reduced regulatory friction through coordinated federal and state oversight</li>
</ul>
<div class="lb-trans"><ul>
<li>为州许可运营商减轻《第 280E 条》税收限制</li>
<li>与现有州许可系统相一致的新快速联邦注册途径</li>
<li>通过协调的联邦和州监管减少监管摩擦</li>
</ul>
</div><p>These changes will allow compliant operators to reinvest in patient care, product quality, and innovation—while strengthening transparency and accountability across the industry.</p>
<div class="lb-trans"><p>这些变化将使合规运营商能够重新投资于患者护理、产品质量和创新，同时增强行业的透明度和问责制。</p>
</div><p><strong>A Foundation for the Future</strong></p>
<div class="lb-trans"><p><strong>未来的基础</strong></p>
</div><p>ACCM emphasizes that this action is not an endpoint, but a foundation for continued progress. The organization will continue working with policymakers, healthcare leaders, and industry stakeholders to advance standards, education, and infrastructure that support safe, effective, and equitable access to medical cannabis.</p>
<div class="lb-trans"><p>ACCM 强调，这一行动不是终点，而是持续进步的基础。该组织将继续与政策制定者、医疗领导者和行业利益相关者合作，推动支持安全、有效和公平获取医疗大麻的标准、教育和基础设施。</p>
</div><p>&#34;Rescheduling cannabis to Schedule III is a long-overdue step that opens the door to real science. For years, researchers have been blocked from studying its full therapeutic potential.&#34; says, Dr. Annabelle Manalo-Morgan, ACCM Research Committee Chairman &#34;Now, we can generate the data, educate responsibly, and ensure that access is guided by evidence — not stigma. This is a win for patients, for science, and for global health.&#34;</p>
<div class="lb-trans"><p>“将大麻重新分类为第三类是一个久违的步骤，为真正的科学打开了大门。多年来，研究人员一直被阻止研究其全部治疗潜力。” ACCM 研究委员会主席安娜贝尔·马纳洛 - 摩根博士表示。“现在，我们可以生成数据，负责任地进行教育，并确保获取是基于证据而非污名。这是患者、科学和全球健康的胜利。”</p>
</div><p>ACCM remains committed to advancing its national initiatives, including the Elevated States program and the Next Frontier platform, to support standardized, compliant, and patient-focused integration of medical cannabis across healthcare and wellness systems.</p>
<div class="lb-trans"><p>ACCM 仍致力于推进其国家倡议，包括提升州计划和下一个前沿平台，以支持医疗大麻在医疗和健康系统中的标准化、合规和以患者为中心的整合。</p>
</div><p><strong>About the American Council of Cannabis Medicine (ACCM)</strong></p>
<div class="lb-trans"><p><strong>关于美国大麻医学委员会 (ACCM)</strong></p>
</div><p>The American Council of Cannabis Medicine is the leading voice for the U.S. medical cannabis industry, representing a coalition of retailers, producers, healthcare professionals, researchers, insurers, patient advocates, and wellness providers. ACCM's Next Frontier program and platform provides the infrastructure system that digitally connects pharmacies, insurers, wellness groups, physicians for patient access.</p>
<div class="lb-trans"><p>美国大麻医学委员会是美国医疗大麻行业的主要声音，代表零售商、生产商、医疗专业人士、研究人员、保险公司、患者倡导者和健康提供者的联盟。ACCM 的下一个前沿计划和平台提供了数字连接药房、保险公司、健康团体和医生以便患者获取的基础设施系统。</p>
</div><p>Founded in 2016 as a Capitol Hill working group, ACCM has evolved into a national organization dedicated to expanding safe, effective, and equitable access to medical cannabis through policy advancement, physician engagement, patient advocacy, and the development of standards that promote patient safety, access, and innovation.</p>
<div class="lb-trans"><p>ACCM 成立于 2016 年，作为国会山的工作组，已发展成为一个国家组织，致力于通过政策推进、医生参与、患者倡导和促进患者安全、获取和创新的标准发展，扩大安全、有效和公平获取医疗大麻的机会。</p>
</div><p><strong>Learn more:</strong></p>
<div class="lb-trans"><p><strong>了解更多：</strong></p>
</div><p><strong>Elevated States Program:</strong> www.elevatedmembership.org <strong>Next Frontier Program:</strong> www.nextfrontier.us</p>
<div class="lb-trans"><p><strong>提升州计划：</strong> www.elevatedmembership.org <strong>下一个前沿计划：</strong> www.nextfrontier.us</p>
</div><p>The <strong>American Council of Cannabis Medicine</strong></p>
<div class="lb-trans"><p><strong>美国大麻医学委员会</strong></p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系人：</strong></p>
</div><p>Lexie Henderson</p>
<div class="lb-trans"><p>莱克西·亨德森</p>
</div><p>202-349-9650 ext. 800</p>
<div class="lb-trans"><p>202-349-9650 ext. 800</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE American Council of Cannabis Medicine</p>
<div class="lb-trans"><p>来源 美国大麻医学委员会</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIzJk5ld3NJdGVtSWQ9UEg0MjM4MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjMxMzExUFJfTkVXU19VU1BSX19fX19QSDQyMzgw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH42380&amp;Transmission_Id=202604231311PR_NEWS_USPR_____PH42380&amp;DateId=20260423"/></p>

美国大麻医学委员会对联邦将大麻重新分类为附表 III 表示赞赏